63.6% of high-risk HPV patients cleared the virus with AHCC

The incidence of Human papillomavirus (HPV) has long worried the medical and scientific community, because it affects a large part of the world’s population. Given this reality, recent research led by Professor Judith Smith, a distinguished academic at the University of Texas at Houston, has discovered the potential of AHCC®, a special mushroom extract, to combat this problem.

Building on these discoveries, Papiloxyl has developed capsules with AHCC® in Europe, now available in pharmacies and specialized centers.

The threat of HPV, in particular strains 16 and 18, the most dangerous and associated with different types of cancer, is palpable: around 80% of sexually active people will be affected at some point in their lives. For women, these strains are primarily associated with the risk of cervical cancer. Men, meanwhile, face the possibility of throat, anal, and penile cancers due to these viral variants.

The investigations of Professor Judith A. Smith, at the University of Texas Health Science Center at Houston, are a beacon of hope in this context. Their detailed studies highlighted the transformative potential of AHCC®.

In a study led by Professor Judith A. Smith, after consuming AHCC® over a period of approximately 6 months 63.6% of people with high-risk HPV infection experienced remission. Additionally, the use of AHCC® resulted in an increase in the number of T lymphocytes, suggesting that AHCC® may fight HPV by regulating the immune system.

Taking note of this development, Papiloxyl has developed an AHCC-based solution for the European market. This compound, rigorously derived from mushrooms and supported by abundant scientific literature, not only aims to strengthen the immune system, but also appears to be a revolutionary proposition in health care. Papiloxyl, through this launch, reaffirms its commitment to the forefront in terms of health and well-being.

Professor Smith highlighted the promise that AHCC® represents, saying: “Incorporating AHCC into health regimens may be essential in helping many patients overcome HPV infection and, therefore, reduce the risk of cancer diseases associated with the virus.”

On the other hand, we find Condyloxyl genital gel, an innovative topical gel presented as a solution in association with AHCC.

In conclusion, strengthening the immune system is essential in the fight against HPV. Immunotherapy is emerging as a powerful strategy, and recent advances suggest that by strengthening our natural defenses, we can move toward effective elimination of the virus. Nature gives us the tools; Science teaches us how to use them to ensure a healthier future.

In conclusion, early detection of HPV is essential as it provides a crucial opportunity to act before the disease progresses. It is imperative that men and women are aware of these risks, get tested regularly, and learn about existing treatments for HPV.


In front. Oncol., June 22, 2022

Gynecological oncology section

Volume 12 – 2022 | https://doi.org/10.3389/fonc.2022.881902

Leave a comment